Adagene Gains NMPA Clearance for ADG138 IND
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
CD3
Advertisement
Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
AbbVie Reports Positive Phase 3 Etentamig Results
North Chicago, Illinois, USA, September 3, 2026 AbbVie has announced positive topline results from the Phase 3 CERVINO trial,...
Astellas Starts Phase 3 Trial of ASP2138 in Gastric Cancer
Tokyo, Japan, August 25, 2026 Astellas Pharma Inc. announced that the first patient has been dosed in a Phase...
Advertisements
Antengene Wins Australian Trial Approval for ATG-201
Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Harbour BioMed Wins NMPA IND Approval for HBM7004
Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...
Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
Genmab and AbbVie Clarify EPCORE DLBCL-1 Phase 3 Results
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
Advertisement
